Next Article in Journal
Detection of Anti-Nucleocapsid Antibody in COVID-19 Patients in Bangladesh Is not Correlated with Previous Dengue Infection
Next Article in Special Issue
Performance of the LIAISON® SARS-CoV-2 Antigen Assay vs. SARS-CoV-2-RT-PCR
Previous Article in Journal
Investigating the Presence of SARS CoV-2 in Free-Living and Captive Animals
Previous Article in Special Issue
Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man
Review

Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2

1
Centre for Experimental and Clinical Regenerative Medicine, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia
2
Laboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia
3
Institute of Neuroimmunology, Slovak Academy of Sciences, 84505 Bratislava, Slovakia
*
Author to whom correspondence should be addressed.
Academic Editor: Lawrence S. Young
Pathogens 2021, 10(6), 636; https://doi.org/10.3390/pathogens10060636
Received: 15 April 2021 / Revised: 11 May 2021 / Accepted: 19 May 2021 / Published: 21 May 2021
(This article belongs to the Collection SARS-CoV Infections)
Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all. View Full-Text
Keywords: SARS-CoV-2; COVID-19; cytokine storm; therapy; antibodies; vaccines SARS-CoV-2; COVID-19; cytokine storm; therapy; antibodies; vaccines
Show Figures

Figure 1

MDPI and ACS Style

Hudakova, N.; Hricikova, S.; Kulkarni, A.; Bhide, M.; Kontsekova, E.; Cizkova, D. Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. Pathogens 2021, 10, 636. https://doi.org/10.3390/pathogens10060636

AMA Style

Hudakova N, Hricikova S, Kulkarni A, Bhide M, Kontsekova E, Cizkova D. Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. Pathogens. 2021; 10(6):636. https://doi.org/10.3390/pathogens10060636

Chicago/Turabian Style

Hudakova, Nikola, Simona Hricikova, Amod Kulkarni, Mangesh Bhide, Eva Kontsekova, and Dasa Cizkova. 2021. "Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2" Pathogens 10, no. 6: 636. https://doi.org/10.3390/pathogens10060636

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop